

AstraZeneca ends collaboration with Targacept

10 October 2014 | News | By Rahul Koul Koul

AstraZeneca ends collaboration with Targacept



AstraZeneca terminated its collaborative research and license agreement with Targacept, a North Carolina-based, US biopharmaceutical company.

The collaboration started in 2005, and is now terminated after nearly 9 years.

The termination becomes effective 90 days after October 8, 2014.

The decision will end the collaboration on TC-6683 compound.

All the rights and licenses on this compound will be returned to Targacept.